The acquisition will give Aetion customers the ability to tap into previously inaccessible, high utility, global health data to conduct transformational healthcare research
Aetion announced that it has acquired Replica Analytics. Through Replica, Aetion will open up new avenues for better understanding treatment pathways, safety, and effectiveness and improve standards of care.
“Replica enhances Aetion’s technology portfolio to open access to previously inaccessible RWD. Our shared belief in rooting technology innovation in scientific rigour assures that together Replica, and Aetion will accelerate the impact of RWE on improving access to higher quality, more affordable healthcare globally,” said Dr Jeremy Rassen, Co-founder and President, Aetion.
Also Read: It’s All About Data Analytics
“Despite the tremendous number of valuable RWD sources, the vast majority of the world’s health data is still inaccessible to researchers because of privacy concerns. Replica’s mission is to protect that privacy while making the world’s health data responsibly accessible for decision-grade RWE. Becoming part of Aetion and its ecosystem enables us to accelerate and expand that mission by deploying our technology with more data sources and in new applications,” said Dr Khaled El Emam, Replica Analytics’ Co-founder and CEO, SVP & General Manager of Replica Analytics at Aetion.
Replica’s advanced technology expands Aetion’s offerings, including its fit-for-purpose data services, by giving customers more privacy-protected data options when using the Aetion Evidence Platform, an essential feature in rare disease and speciality research.
